Capecitabine in Combination With Aromatase Inhibitor Versus Aromatase Inhibitors, in Hormonal Receptor Positive Recurrent or Metastatic Breast Cancer Patients, Randomized Controlled Study

NCT04012918 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

124

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Breast Cancer

Interventions

DRUG: Capecitabine plus aromatase inhibitor
DRUG: A.I.

Sponsor

Ain Shams University